Status:
UNKNOWN
Human Menstrual Blood-derived Mesenchymal Stem Cells for Patients With Liver Cirrhosis
Lead Sponsor:
S-Evans Biosciences Co., Ltd.
Collaborating Sponsors:
Zhejiang University
Zhejiang General Hospital of Armed Police
Conditions:
Liver Cirrhosis
Fibrosis
Eligibility:
FEMALE
20-50 years
Phase:
PHASE1
PHASE2
Brief Summary
Orthotopic liver transplantation (OLT) is currently the most effective method for end-stage liver diseases. However, the critical shortage of donor organs, high cost, and the problem of immune rejecti...
Detailed Description
The purpose of this study is to show whether menstrual blood-derived stem cells can improve the disease conditions in patients with liver cirrhosis. One of two treatment arms will be assigned to the ...
Eligibility Criteria
Inclusion
- Written informed consent
- Aged 20 to 50years
- Liver cirrhosis
- Negative pregnancy test
Exclusion
- Pregnant or lactating women
- Malignancies
- Sepsis
- Vital organs failure
- Severe bacteria infection
- Vascular thromboses in the portal or hepatic veins
Key Trial Info
Start Date :
October 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2015
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT01483248
Start Date
October 1 2010
End Date
October 1 2015
Last Update
June 7 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
the First Affiliated Hospital of Zhejiang University-IRB
Hangzhou, Zhejiang, China, 310003